Beijing, China - Jan 15, 2021 (CCTV - No access Chinese mainland)
1. Press briefing in progress
2. Various of reporters

FILE: China - Date Unknown (CGTN - No access Chinese mainland)
3. Sinopharm sign
4. Various of vials of Sinopharm's coronavirus vaccine

FILE: China - 2020 (CCTV - No access Chinese mainland)
5. Various of COVID-19 vaccine production line

FILE: Exact Date and Location Unknown (China National Biotec Group Company - No access Chinese mainland)
6. Various of researchers working in lab

Beijing, China - Jan 15, 2021 (CCTV - No access Chinese mainland)
7. SOUNDBITE (Chinese) Zhao Lijian, spokesman, Ministry of Foreign Affairs (starting with shots 3-6):
"Some Chinese vaccines do not require ultra-low temperatures for cold-chain shipment and storage. For the vast majority of countries, especially developing countries, Chinese vaccines hold a stronger appeal in this regard. In addition, the Chinese vaccines have good efficacy and safety data. Vaccines are mankind's most powerful weapon to vanquish the pandemic. The Chinese government attaches high importance to COVID-19 vaccine research and development. Relevant government departments, vaccine companies, research institutes, and medical facilities are directed to put people and life first, take safety as the top principle, and strengthen quality control. Coordinated efforts have been made to advance vaccine research and development and medical support for vaccination."

FILE: Exact Date and Location Unknown (China National Biotec Group Company - No access Chinese mainland)
8. Various of researchers working in lab

Beijing, China - Jan 15, 2021 (CCTV - No access Chinese mainland)
9. SOUNDBITE (Chinese) Zhao Lijian, spokesman, Ministry of Foreign Affairs:
"At present, the 14 Chinese vaccines in clinical trials, including five in Stage III trials, all have proven their safety through earlier animal tests, Stage I, II and III trials. There are also studies whose results have been published by well-known journals and recognized by the World Health Organization, and other countries."

FILE: Beijing, China - Sept 6, 2020 (Guangdong Radio and Television Station - No access Chinese mainland)
10. Various of inactivated COVID-19 vaccine on display at stall of CNBG at China International Fair for Trade in Services (CIFTIS)

Beijing, China - Jan 15, 2021 (CCTV - No access Chinese mainland)
11. SOUNDBITE (Chinese) Zhao Lijian, spokesman, Ministry of Foreign Affairs:
"China has pledged that COVID-19 vaccine development and deployment in China, when available, will be made a global public good that helps to ensure vaccine accessibility and affordability in developing countries."

Shanghai, China - Jan 6, 2021 (CCTV - No access Chinese mainland)
12. Sign reading (Chinese) "COVID-19 Vaccination Room"
13. Various of people getting vaccinated for COVID-19

Chinese COVID-19 vaccines are advantageous in terms of both storage and shipment compared with their western counterparts, Foreign Ministry spokesman Zhao Lijian said on Friday.

Zhao made the remarks at a regular press conference when answering a question about the advantages of Chinese vaccines compared with vaccines from the U.S. and UK in regards to production, storage, and shipment.

"Some Chinese vaccines do not require ultra-low temperatures for cold-chain shipment and storage. For the vast majority of countries, especially developing countries, Chinese vaccines hold a stronger appeal in this regard. In addition, the Chinese vaccines have good efficacy and safety data. Vaccines are mankind's most powerful weapon to vanquish the pandemic. The Chinese government attaches high importance to COVID-19 vaccine research and development. Relevant government departments, vaccine companies, research institutes, and medical facilities are directed to put people and life first, take safety as the top principle, and strengthen quality control. Coordinated efforts have been made to advance vaccine research and development and medical support for vaccination," said Zhao.

"At present, the 14 Chinese vaccines in clinical trials, including five in Stage III trials, all have proven their safety through earlier animal tests, Stage I, II and III trials. There are also studies whose results have been published by well-known journals and recognized by the World Health Organization, and other countries," he added.

China has pledged that COVID-19 vaccine development and deployment in China, when available, will be made a global public good that helps to ensure vaccine accessibility and affordability in developing countries, he said.